Haakensen, Vilde Drageset
Nowak, Anna K.
Ellingsen, Espen Basmo
Farooqi, Saima Jamil
Bjaanæs, Maria Moksnes
Horndalsveen, Henrik
Mcculloch, Tine
Grundberg, Oscar
Cedres, Susana M.
Helland, Åslaug http://orcid.org/0000-0002-5520-0275
Clinical trials referenced in this document:
Documents that mention this clinical trial
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
https://doi.org/10.1136/jitc-2021-004345
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
https://doi.org/10.1186/s12967-021-02905-3
Funding for this research was provided by:
Helse Sør-Øst RHF (2021083, 2020077)
Ultimovacs
Bristol-Myers Squibb
Article History
Received: 10 April 2021
Accepted: 22 May 2021
First Online: 31 May 2021
Declarations
:
: The trial is approved by the regional ethics committee (20/47804). All patients sign informed consent after receiving oral and written information and can withdraw from the study at any time point. The study is performed in compliance with the World Medical Association Declaration of Helsinki and ICH E6 for Good Clinical Practice and is approved by the regional ethics committee.
: All authors have consented to the publication. Approval has also been obtained from BMS and Ultimovacs.
: EBE is employed by Ultimovacs ASA. AKN has participated as a consultant for Bristol Meyers Squibb. The remaining authors declare that they have no competing interests.